A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung Cancer

Background Lung cancer is the leading cause of cancer mortality worldwide, yet the therapeutic strategy for advanced non-small cell lung cancer (NSCLC) is limitedly effective. In addition, validated histone deacetylase (HDAC) inhibitors for the treatment of solid tumors remain to be developed. Here, we propose a novel HDAC inhibitor, OSU-HDAC-44, as a chemotherapeutic drug for NSCLC. Methodology/Principal Findings The cytotoxicity effect of OSU-HDAC-44 was examined in three human NSCLC cell lines including A549 (p53 wild-type), H1299 (p53 null), and CL1-1 (p53 mutant). The antiproliferatative mechanisms of OSU-HDAC-44 were investigated by flow cytometric cell cycle analysis, apoptosis assays and genome-wide chromatin-immunoprecipitation-on-chip (ChIP-on-chip) analysis. Mice with established A549 tumor xenograft were treated with OSU-HDAC-44 or vehicle control and were used to evaluate effects on tumor growth, cytokinesis inhibition and apoptosis. OSU-HDAC-44 was a pan-HDAC inhibitor and exhibits 3–4 times more effectiveness than suberoylanilide hydroxamic acid (SAHA) in suppressing cell viability in various NSCLC cell lines. Upon OSU-HDAC-44 treatment, cytokinesis was inhibited and subsequently led to mitochondria-mediated apoptosis. The cytokinesis inhibition resulted from OSU-HDAC-44-mediated degradation of mitosis and cytokinesis regulators Auroroa B and survivin. The deregulation of F-actin dynamics induced by OSU-HDAC-44 was associated with reduction in RhoA activity resulting from srGAP1 induction. ChIP-on-chip analysis revealed that OSU-HDAC-44 induced chromatin loosening and facilitated transcription of genes involved in crucial signaling pathways such as apoptosis, axon guidance and protein ubiquitination. Finally, OSU-HDAC-44 efficiently inhibited A549 xenograft tumor growth and induced acetylation of histone and non-histone proteins and apoptosis in vivo. Conclusions/Significance OSU-HDAC-44 significantly suppresses tumor growth via induction of cytokinesis defect and intrinsic apoptosis in preclinical models of NSCLC. Our data provide compelling evidence that OSU-HDAC-44 is a potent HDAC targeted inhibitor and can be tested for NSCLC chemotherapy.

[1]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[2]  John Calvin Reed,et al.  Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. , 2000, Science.

[3]  Gordon K Smyth,et al.  Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[5]  D. Dowbenko,et al.  The Forkhead Transcription Factor AFX Activates Apoptosis by Induction of the BCL-6 Transcriptional Repressor* , 2002, The Journal of Biological Chemistry.

[6]  S. Thibodeau,et al.  Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. , 2005, Chest.

[7]  Eun Ryoung Jang,et al.  Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells. , 2005, Cancer research.

[8]  John Calvin Reed,et al.  Conversion of Bcl-2 from Protector to Killer by Interaction with Nuclear Orphan Receptor Nur77/TR3 , 2004, Cell.

[9]  Weidong Wang,et al.  Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. , 2002, Genes & development.

[10]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Richard Pazdur,et al.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.

[12]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[13]  Marie Joseph,et al.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Socinski,et al.  Current treatments for advanced stage non-small cell lung cancer. , 2009, Proceedings of the American Thoracic Society.

[15]  Y. Rao,et al.  Signal Transduction in Neuronal Migration Roles of GTPase Activating Proteins and the Small GTPase Cdc42 in the Slit-Robo Pathway , 2001, Cell.

[16]  M. Glotzer,et al.  The Molecular Requirements for Cytokinesis , 2005, Science.

[17]  K. Bhalla.  Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Andrew J. Wilson,et al.  Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. , 2010, Cancer research.

[19]  M. Hendrix,et al.  Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. , 1997, American journal of respiratory cell and molecular biology.

[20]  G. Giaccone,et al.  Global histone modifications predict prognosis of resected non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[22]  R. Medema,et al.  The case for Survivin as mitotic regulator. , 2006, Current opinion in cell biology.

[23]  P. Atadja,et al.  Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. , 2009, Blood.

[24]  Asad Umar,et al.  Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. , 2004, Journal of medicinal chemistry.

[25]  S. Marsoni,et al.  A work in progress: The clinical development of histone deacetylase inhibitor , 2008, Epigenetics.

[26]  R C Coombes,et al.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  G. Giaccone,et al.  Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients , 2006, Molecular Cancer Therapeutics.

[28]  D. Canes,et al.  Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo , 2005, International journal of cancer.

[29]  L. Ngo,et al.  Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Earnshaw,et al.  The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.

[31]  L. Tanoue.  Clinical Features of 5,628 Primary Lung Cancer Patients: Experience at Mayo Clinic From 1997 to 2003Yang P, Allen MS, Aubry MC, et al (Mayo Clinic, Rochester, Minn) Chest 128:452-462, 2005§ , 2007 .

[32]  F. D. De Braud,et al.  Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer , 2003, Pharmacological Reviews.

[33]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[35]  K. Glaser,et al.  Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. , 2003, Molecular cancer therapeutics.